We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » INDEPENDENT MOAs SEEN AS FUTURE FOR COMBO PRODUCTS
INDEPENDENT MOAs SEEN AS FUTURE FOR COMBO PRODUCTS
May 6, 2004
The FDA envisions the pipeline of combination products moving from the typical current effort to improve the safety, efficacy or ease of use of a drug, device or biologic to a future in which combination products would pursue two or more separate therapeutic benefits.